At present, only anti-PD-1 is approved for treating CRC patients with unresectable or metastatic dMMR/MSI-H tumors, and only recently approved as a first-line treatment in these patients, based on KEYNOTE-177 study [17,18]. This evidence concerns the gene PDCD1 and colorectal carcinoma.